title: Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.
abstract: OBJECTIVE
  Several recent studies have shown that oligometastatic disease has curative potential, although it was previously considered to signal a patient's last stage of life. Stereotactic body radiotherapy has been available for extra-cranial metastases in addition to stereotactic cranial radiotherapy for brain metastases. The aim of the present study was to retrospectively evaluate the clinical outcomes of stereotactic radiotherapy for patients with oligometastatic lesions.
  
  
  METHODS
  Between 1999 and 2008, 41 patients with five or fewer detectable metastases were treated with stereotactic radiotherapy at our institution. The treated oligometastatic lesions were in the brain, lung and adrenal glands.
  
  
  RESULTS
  With a median follow-up period of 20 months, the 3-year overall survival, progression-free survival, local control and distant control rates were 39%, 20%, 80% and 35%, respectively, and the respective 5-year rates were 28%, 20%, 80% and 35%. The median survival time was 24 months. According to interval to recurrence, the 3- and 5-year overall survival rates were 19% and 10%, respectively, for patients with <12 months (n = 18), compared with 53% and 40% for those with > or =12 months (n = 23) (P = 0.006).
  
  
  CONCLUSIONS
  Precise stereotactic radiotherapy was effective in controlling oligometastatic lesions for patients with a median survival time of 24 months. Interval to recurrence may impact the overall survival rate and should be included in the stratification criteria in a prospective randomized trial to investigate the benefits of stereotactic radiotherapy for patients with oligometastases.
authors.affiliation: Department of Radiology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan. t-inoue@med.hokudai.ac.jp
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Inoue
authors.forename: Norio
authors.initials: N
authors.lastname: Katoh
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Aoyama
authors.forename: Rikiya
authors.initials: R
authors.lastname: Onimaru
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Taguchi
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Onodera
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shirato
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000473:pathology / Q000528:radiation effects; D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000209:etiology; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D011832:Radiation Injuries / Q000209:etiology / Q000473:pathology; D016634:Radiosurgery / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome